Moody's Ratings (Moody's) has today assigned Baa2 senior unsecured ratings to UK-based medical products and devices manufacturer Smith & Nephew plc's (Smith & Nephew or the company) new USD notes issue. The notes will have a split maturity, of three and ten years. The existing long-term issuer ratin...
Moody's Investors Service ("Moody's") has assigned a Baa2 senior unsecured rating to Smith & Nephew plc's (S&N, Smith & Nephew or the company) proposed €500 million notes. The offering marks Smith & Nephew plc's debut in the public Eurobond market. Proceeds from the new proposed notes will be used f...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Smith& Nephew plc. Global Credit Research- 08 Dec 2021. London, 08 December 2021-- Moody's Investors Service has completed a periodic review of the ratings of Smith& Nephew plc and other ratings that are associated with the same analytical unit.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Smith& Nephew plc. Global Credit Research- 15 Jan 2021. London, 15 January 2021-- Moody's Investors Service has completed a periodic review of the ratings of Smith& Nephew plc and other ratings that are associated with the same analytical unit.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Rating Action: Moody's assigns Baa2 senior unsecured rating to Smith& Nephew's notes offering. Global Credit Research- 07 Oct 2020. London, 07 October 2020-- Moody's Investors Service has assigned a first time Baa2 senior unsecured rating to Smith& Nephew plc's proposed new notes, to be issued in the aggregate amount of $1 billion.
Rating Action: Moody's assigns Baa2 issuer rating to Smith& Nephew plc; outlook stable. Global Credit Research- 05 Oct 2020. London, 05 October 2020-- Moody's Investors Service has assigned a Baa2 first time long-term issuer rating to UK-based medical products and devices manufacturer Smith& Nephew plc.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
While we continue to think Smith & Nephew faces key challenges in remaining an independent, mid-sized company in a medical technology world that has come to reward consolidation and scale, we like the steps new CEO Namal Nawana has taken to broaden the firm’s product portfolio into adjacent and complimentary markets. These additions do not necessarily widen Smith & Nephew’s narrow economic moat, but they help to reinforce the firm’s competitive position in advanced wound care, in our opini...
While we continue to think Smith & Nephew faces key challenges in remaining an independent, mid-sized company in a medical technology world that has come to reward consolidation and scale, we like the steps new CEO Namal Nawana has taken to broaden the firm’s product portfolio into adjacent and complimentary markets. These additions do not necessarily widen Smith & Nephew’s narrow economic moat, but they help to reinforce the firm’s competitive position in advanced wound care, in our opi.....
Smith & Nephew's impressive innovation has allowed the company to carve out a slice of the orthopedic and wound-care markets. Though Smith & Nephew is smaller than the dominant orthopedic competitors, it has been a strong contributor in terms of introducing meaningful innovation with its pioneering hip resurfacing implant and knee replacements with Verilast technology, which the firm contends can last for 30 years. These are significant improvements that exceed the evolutionary innovation typica...
Smith & Nephew finished up 2018 not materially far off from our projections and we’re leaving our fair value unchanged for now. Similar to previous quarters, large joint implants continued to lag market growth in the fourth quarter. Accounting for roughly one third of total revenue, quarterly knees and hips rose 3% on an underlying basis, which was then whittled down to 1% by foreign exchange headwinds. The main bright spots came in the form of sports medicine, the Navio hand-held orthopedic.....
Smith & Nephew finished up 2018 not materially far off from our projections and we’re leaving our fair value unchanged for now. Similar to previous quarters, large joint implants continued to lag market growth in the fourth quarter. Accounting for roughly one third of total revenue, quarterly knees and hips rose 3% on an underlying basis, which was then whittled down to 1% by foreign exchange headwinds. The main bright spots came in the form of sports medicine, the Navio hand-held orthopedic r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.